Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Actelion Q1 GAAP Profit Slumps; Backs 2012 Core Earnings View - Quick Facts

Swiss pharmaceutical firm Actelion Ltd. (ALIOF.PK) reported a plunge in its first-quarter GAAP net income to 45.06 million Swiss francs or 0.38 Swiss francs per share from the prior year's 146.29 million Swiss francs or 1.20 Swiss francs per share. Core earnings per share declined 31% to 0.66 Swiss francs during the latest quarter.

Total net revenue slipped to 417.47 million Swiss francs from 528.23 million Swiss francs a year earlier.

Product sales for the quarter reached 415.8 million Swiss francs, compared with 450.1 million Swiss francs last year, down by 4% in local currencies. In addition, the company reaffirmed its 2012 flat core earnings forecast.

Click here to receive FREE breaking news email alerts for Actelion Ltd., and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Germany's EU measure of inflation unexpectedly slowed in October after holding steady in the previous two months, preliminary estimates from Destatis showed Thursday. The harmonized index of consumer prices rose 0.7 percent annually following 0.8 percent increase in each of the previous three months.... First-time claims for U.S. unemployment benefits saw a modest increase in the week ended October 25th, according to a report released by the Labor Department on Thursday. The report said initial jobless claims edged up to 287,000, an increase of 3,000 from the previous week's revised level of 284,000. Stocks may move to the downside in early trading on Thursday, adding to the modest losses posted in the previous session. The major index futures are currently pointing to a modestly lower open for the markets, with the Dow futures down by 30 points.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.